Kringle Pharma, Inc. provided earnings guidance for the fiscal year ending September 30, 2024. For the year, the company expects net sales of JPY 272 million, operating loss of JPY 1,133 million, loss of JPY 1,109 million and basic loss per share of JPY 180.12.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
595 JPY | -2.62% | -8.46% | -20.88% |
1st Jan change | Capi. | |
---|---|---|
-20.88% | 2.49Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.66% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- 4884 Stock
- News Kringle Pharma, Inc.
- Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024